Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
Phase 4 Completed
6,051 enrolled 11 charts
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
Phase 3 Completed
1,100 enrolled
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Phase 2 Completed
780 enrolled
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Phase 1 Completed
160 enrolled
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
Phase 1/2 Completed
34 enrolled
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Phase 4 Completed
540 enrolled
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
Phase 3 Completed
237 enrolled 20 charts
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Phase 4 Completed
873 enrolled 34 charts
V503-010
Phase 3 Completed
1,518 enrolled 44 charts
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Phase 3 Completed
1,042 enrolled 26 charts